Michael Amylon
Academic Appointments
- Emeritus (Active) Professor, Pediatrics - Stem Cell Transplantation
Contact Information
-
Clinical Offices
Pediatric Hematology/Oncology 725 Welch Rd Palo Alto, CA 94304 Tel Work (650) 725-9250 Fax (650) 497-8101Practices at Lucile Packard Children's Hospital
Professional Snapshot
Clinical Focus
- Pediatric Hematology-Oncology
- Ped Hematology/Oncology
Professional Education
| Board Certification: | Pediatric Hematology-Oncology, American Board of Pediatrics (1982) |
| Fellowship: | SUMC - Graduate Medical Education, CA (1981) |
| Board Certification: | General Pediatrics, American Board of Pediatrics (1980) |
| Residency: | SUMC - Graduate Medical Education, CA (1979) |
| Internship: | SUMC - Graduate Medical Education, CA (1977) |
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information
| Consulting: | TOM PETRUS & MILLER, LLLC |
Scientific Focus
Current Research Interests
Bone marrow transplantation (BMT) is a treatment modality which is being broadly applied to a growing number of disorders. Increasing success with BMT is offering improved survival to pediatric and adult patients with acute leukemia, chronic leukemia, lymphomas, and a variety of solid tumors as well as severe aplastic anemia. In the pediatric population, a variety of congenital disorders such as immunodeficiency syndromes, bone marrow failure states, hemoglobinopathies and inborn errors of metabolism can also be successfully treated with BMT. Identification of appropriate marrow donors (within or outside of the family) and the increasing use of autologous stem cells with or without purging have made this treatment approach available to more and more patients. Future studies will concentrate on control and prevention of graft-versus-host disease, ablation of malignant cells, and gene-transfer utilizing marrow stem cells as the vector.
T-cell Acute Lymphoblastic Leukemia and advanced stage Lymphoblastic Lymphoma are rare malignancies which affect pre-teen and teen-aged children with a male preponderance. These entities are closely related biologically, and probably represent different ends of a spectrum of T-cell malignancies. Treatment approaches taking advantage of the biological similarities of these entities have been successful in improving survival for affected children. Further studies of innovative approaches (immunotoxins, monoclonal antibody targeting, tumor antigen vaccination) as well as randomized clinical trials defining better chemotherapeutic regimens are ongoing. All patients entered in these protocols for treatment also participate in biologic studies utilizing molecular markers of minimal residual disease and classification studies at diagnosis and relapse including complete immunophenotyping and cytogenetics as well as classical morphology and histochemistry.
Clinical Trials
Publications
- Projective drawings as measures of psychosocial functioning in siblings of pediatric cancer patients from the Camp Okizu study. J Pediatr Oncol Nurs. 2008 Jan-Feb; (1): 44-55
- Safety of hematopoietic stem cell transplantation in children less than three years of age. Pediatr Hematol Oncol. 2008; (8): 705-22
- Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group pilot feasibility study. J Pediatr Hematol Oncol. 2006; (4): 210-5
- Siblings of pediatric cancer patients: the quantitative and qualitative nature of quality of life. J Psychosoc Oncol. 2005; (1): 87-108
- High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol. 2004; (22): 4532-40
Help